ArticleNPJ breast cancer2025

Real-world effectiveness of PARP inhibitors after CDK4/6 inhibitor therapy in BRCA-mutated HR-positive/HER2-negative advanced breast cancer.

Emma Zattarin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.